Education
About Us
Working with TipRanks
Follow Us
Equasens (FR:EQS)
:EQS
EQS Stock Chart & Stats
Day’s Range― - ―
52-Week Range€34.60 - €67.40
Previous CloseN/A
Volume720.00
Average Volume (3M)15.20K
Market Cap
€542.24M
Enterprise Value€810.69M
Total Cash (Recent Filing)€14.93M
Total Debt (Recent Filing)€65.45M
Price to Earnings (P/E)12.8
Beta0.45
Next Earnings
Sep 26, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jul 02, 2024Dividend Yield3.46%
Share Statistics
EPS (TTM)2.81
Shares Outstanding15,174,125
10 Day Avg. Volume14,581
30 Day Avg. Volume15,202
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.38
Price to Cash Flow (P/CF)21.50
P/FCF Ratio75.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.00Price Target Upside107.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Equasens News
---
Bulls Say, Bears Say
Bulls Say
Market ShareEquasens gaining market share in H2 in a better environment for French pharmacies.
New Product LaunchesThere are enough drivers in 2025-26 to trust the company can grow in high single digits or low double-digit organic growth, including new hardware sales and product launches in multiple countries.
Regulatory Tailwinds2025 should be a strong year with the planned launch of the digital healthcare card in France, which will require healthcare professionals to invest in new QR-code card readers.
Revenue GrowthEquasens saw its 4Q24 revenue come in 1% ahead of expectations.
Bears Say
Guidance MissEquasens missed on Q3 expectations, with Q3 coming in 7% lower than management guidance.
ProfitabilityThe weaker Q3 revenue should result in weaker-than-anticipated profitability in H2.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.19%
Mutual Funds
― Other Institutional Investors
97.27% Public Companies and
Individual Investors
EQS FAQ
What was Equasens’s price range in the past 12 months?
Equasens lowest stock price was €34.60 and its highest was €67.40 in the past 12 months.
What is Equasens’s market cap?
Equasens’s market cap is €542.24M.
When is Equasens’s upcoming earnings report date?
Equasens’s upcoming earnings report date is Sep 26, 2025 which is in 179 days.
How were Equasens’s earnings last quarter?
Currently, no data Available
Is Equasens overvalued?
According to Wall Street analysts Equasens’s price is currently Undervalued.
Does Equasens pay dividends?
Equasens pays a Annually dividend of €1.25 which represents an annual dividend yield of 3.46%. See more information on Equasens dividends here
What is Equasens’s EPS estimate?
Equasens’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Equasens have?
Equasens has 15,174,125 shares outstanding.
What happened to Equasens’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Equasens?
Currently, no hedge funds are holding shares in FR:EQS
---
Company Description
Equasens
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
---
EQS Stock 12 Month Forecast
Average Price Target
€75.00
▲(107.76% Upside)
Technical Analysis
Best Analysts Covering EQS
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-24.16%
reiterated a buy rating 2 months ago
Copying David Vignon's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -24.16% per trade.
---